Assessment of biotechnology drugs: what are the issues?
- 1 May 1999
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 47 (3) , 255-274
- https://doi.org/10.1016/s0168-8510(99)00017-2
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Colony-Stimulating Factors and Peripheral Blood Progenitor Cell TransplantationPharmacoEconomics, 1996
- Economic evaluation and health care decision-makingHealth Policy, 1996
- An economic model to assess the savings from a clinical application of haematopoietic growth factorsEuropean Journal Of Cancer, 1996
- Cost-effectiveness comparisons using “real world” randomized trials: The case of new antidepressant drugsJournal of Clinical Epidemiology, 1995
- Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (Filgrastim); a Less costly alternative to autologous bone marrow transplantationEuropean Journal Of Cancer, 1994
- The HA-1A saga: The scientific and ethical dilemma of innovative and costly therapiesIntensive Care Medicine, 1994
- Introduction of new technology into critical care practiceCritical Care Medicine, 1993
- Challenge to growth hormone trialNature, 1993
- Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer ChemotherapyJNCI Journal of the National Cancer Institute, 1993
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal Of Cancer, 1993